生产企业：Astellas Pharma
ASP-3082 (setidegrasib) is an investigational KRAS G12D-targeted protein degrader developed by Astellas Pharma, currently in phase 3 clinical development for non-small cell lung cancer and pancreatic cancer.
ASP-3082 (setidegrasib) is an investigational KRAS G12D-targeted protein degrader developed by Astellas Pharma, currently in phase 3 clinical development for non-small cell lung cancer and pancreatic cancer.
KRAS G12D-targeted protein degrader
ASP-3082 (setidegrasib) is being investigated in phase 3 clinical trials for non-small cell lung cancer (NSCLC) and pancreatic cancer.
共 2 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
